Methyl 4-(1-methoxycarbonylpyrrolidin-3-yl)benzoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: Methyl 4-(1-methoxycarbonylpyrrolidin-3-yl)benzoate
• 英文别名: methyl 3-(4-methoxycarbonylphenyl)pyrrolidine-1-carboxylate
• 化学式: C₁₄H₁₇NO₄
• 分子量: 263.293
• InChiKey: VLIWPKHBVFHGSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Methyl 4-(1-methoxycarbonylpyrrolidin-3-yl)benzoate 、 2-(叔丁氧羰基氧亚氨基)-2-苯乙腈 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 水 、 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 55.0h， 生成 4-(1-(叔丁氧基羰基)吡咯烷-3-基)苯甲酸
  参考文献：
  名称：

  EP1577302

  摘要：

  公开号：
• 作为产物：
  描述：

  4-carbomethoxyphenyl triflate 、 1-(methoxycarbonyl)-3-pyrroline 在 palladium diacetate 、 三(2-呋喃基)膦 、 palladium 10% on activated carbon N,N-二异丙基乙胺 、 lithium chloride 、 甲酸铵 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 20.0h， 以25%的产率得到Methyl 4-(1-methoxycarbonylpyrrolidin-3-yl)benzoate
  参考文献：
  名称：

  EP1577302

  摘要：

  公开号：

文献信息

• NOVEL SULFONYL DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1104754A1

  公开（公告）日：2001-06-06

  Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

  以下是通用公式（I）所代表的磺酰衍生物：Q1-Q2-T1-Q3-SO2-QA以及含有这些衍生物的药物（其中Q1是可选择地取代的饱和或不饱和的五元或六元环烃基团，五元或六元杂环基团等；Q2是单键，氧，硫，C1-C6烷基或类似物；QA是可选择地取代的芳基烯烃基团，杂环芳基烯烃基团或类似物；T1是羰基或类似物）。这些化合物具有强大的FXa抑制作用，并通过口服迅速产生令人满意且持久的抗血栓作用，因此可作为几乎不伴随副作用的抗凝血剂。
• Sulfonyl derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US06525042B1

  公开（公告）日：2003-02-25

  Sulfonyl derivatives represented by general formula (I), salts of the same, and solvates of both: and application of them as drugs: [wherein R1 is hydrogen, hydroxyl, nitro or the like; R2 and R3 are each independently hydrogen, halogeno or the like; R4 and R5 are each dependently hydrogen, halogeno or the like; Q1 is an optionally substituted saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group or the like; Q2 is a single bond, oxygen or the like; Q3 is, e.g., a group represented by formula (a): T1 is carbonyl or the like; and X1 and X2 are each independently methylidyne or nitrogen]. These compounds exhibit potent Fxa inhibiting activities and serve as excellent anticoagulants which speedily exert satisfactory and persistent anti-thrombotic effects through oral administration and little cause adverse effects.

  通用公式(I)表示的磺酰衍生物，其盐以及两者的溶剂化合物：以及它们作为药物的应用：[其中R1是氢、羟基、硝基或类似物；R2和R3各自独立地是氢、卤素或类似物；R4和R5各自依赖于氢、卤素或类似物；Q1是可选择取代的饱和或不饱和的5-或6-成员环烃基或类似物；Q2是单键、氧或类似物；Q3是，例如，由公式(a)表示的基团：T1是羰基或类似物；X1和X2各自独立地是甲基亚砜或氮。这些化合物表现出强大的Fxa抑制活性，并作为优秀的抗凝血剂，通过口服迅速产生令人满意且持久的抗血栓效果，并几乎不引起不良反应。
• Novel sulfonyl derivatives
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：US20040082611A1

  公开（公告）日：2004-04-29

  Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q 1 -Q 2 -T 1 -Q 3 -SO 2 -Q A (I) [wherein Q 1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q 2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C 1-6 alkylene group or the like; Q A represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T 1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.

  本发明描述了一种由以下式(I)表示的磺酰基衍生物： Q1-Q2-T1-Q3-SO2-QA(I) [其中，Q1表示饱和或不饱和的5-或6-环烃基、5-或6-杂环基、二环融合环或三环融合环基，可能具有取代基；Q2表示单键、氧原子、硫原子、线性或支链的C1-6烷基等；QA表示可能具有取代基的芳基烯基或杂芳基烯基；T1表示羰基基团或类似物]，以及包含该化合物的药物。该化合物具有强烈的FXa抑制作用，口服后提供快速、充分和持久的抗血栓效果，并且具有低副作用，因此可用作优秀的抗凝剂。
• Novel ethylenediamine derivatives
  申请人：Nakamoto Yumi

  公开号：US20070129371A1

  公开（公告）日：2007-06-07

  A compound represented by the following formula (1): Q 1 —Q 2 —T o —N(R 1 )—Q 3 —N(R 2 )—T 1 —Q 4 ( 1 ) [wherein, R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: —C(R 3a )(R 4a )—C(R 3b )(R 4b )}m 1 —C(R 3c )(R 4c )}m 2 —C(R 3d )(R 4d )}m 3 —C(R 3e )(R 4e )}m 4 —C (R 3f )(R 4f )— (in which, R 3a to R 4e represent hydrogen or the like); T 0 represents a carbonyl group or the like; and T 1 represents —COCONR— or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  以下化合物公式（1）表示的化合物：Q1-Q2-To-N（R1）-Q3-N（R2）-T1-Q4（1）[其中，R1和R2是氢原子或类似物；Q1是饱和或不饱和的5或6元环烃基，可以具有取代基或类似物；Q2是单键或类似物；Q3表示以下基团：-C（R3a）（R4a）-C（R3b）（R4b）}m1-C（R3c）（R4c）}m2-C（R3d）（R4d）}m3-C（R3e）（R4e）}m4-C（R3f）（R4f）-（其中，R3a到R4e代表氢或类似物）；T0表示羰基基团或类似物；T1表示-COCONR-或类似物]；或其盐，溶剂化合物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥漫性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固。
• NOVEL ETHYLENEDIAMINE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1577302A1

  公开（公告）日：2005-09-21

  A compound represented by the following formula (1):Q1-Q2-To-N(R1)-Q3-N(R2)-T1-Q4 [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-C(R3b)(R4b)}m1-C(R3c)(R4c)}m2-C(R3d)(R4d)}m3-C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  下式(1)代表的化合物：Q1-Q2-To-N(R1)-Q3-N(R2)-T1-Q4 [其中，R1 和 R2 是氢原子或类似物；Q1 是饱和或不饱和的 5 或 6 位环烃基团，该基团可具有取代基或类似物；Q2 是单键或类似物；Q3 代表以下基团：-C(R3a)(R4a)-C(R3b)(R4b)}m1-C(R3c)(R4c)}m2-C(R3d)(R4d)}m3-C(R3e)(R4e)}m4-C(R3f)(R4f)-（其中，R3a 至 R4e 代表氢或类似物）；T0 代表羰基或类似物；T1 代表 -COCONR- 或类似物]；或其盐、其溶液或其 N-氧化物。 该化合物可用作脑梗塞、脑栓塞、心肌梗塞、心绞痛、肺梗塞、肺栓塞、布格氏病、深静脉血栓形成、弥散性血管内凝血综合征的预防和/或治疗剂、瓣膜或关节置换术后血栓形成、血管成形术后血栓形成和再闭塞、全身炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环过程中血栓形成或抽血时血液凝固。